ReviewNature reviews. Urology2016
Bladder cancer: Angiogenesis as a therapeutic target in urothelial carcinoma.
Review in Nature reviews. Urology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- What Genetics Can Do for Oncological Imaging: A Systematic Review of the Genetic Validation Data Used in Radiomics Studies.International journal of molecular sciences · 2022Pooled it
- The VEGF expression associated with prognosis in patients with intrahepatic cholangiocarcinoma: a systematic review and meta-analysis.World journal of surgical oncology · 2022Pooled it
- A Phase II Clinical Trial of TRC105 (Anti-Endoglin Antibody) in Adults With Advanced/Metastatic Urothelial Carcinoma.Clinical genitourinary cancer · 2017Trial
- The interplay between angiogenesis-associated genes and molecular, clinical, and immune features in bladder cancer.Discover oncology · 2025Article
- An angiogenesis‑related lncRNA signature for the prognostic prediction of patients with bladder cancer and LINC02321 promotes bladder cancer progression via the VEGFA signaling pathway.Molecular medicine reports · 2023Article
- Bladder Cancer-Derived Small Extracellular Vesicles Promote Tumor Angiogenesis by Inducing HBP-Related Metabolic Reprogramming and SerRS O-GlcNAcylation in Endothelial Cells.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2022Article
- A novel risk score model based on five angiogenesis-related long non-coding RNAs for bladder urothelial carcinoma.Cancer cell international · 2022Article
- Occludin facilitates tumour angiogenesis in bladder cancer by regulating IL8/STAT3 through STAT4.Journal of cellular and molecular medicine · 2022Article
- Prognostic Value of Vascular-Expressed PSMA and CD248 in Urothelial Carcinoma of the Bladder.Frontiers in oncology · 2021Article
- Epigenetics of Bladder Cancer: Where Biomarkers and Therapeutic Targets Meet.Frontiers in genetics · 2019Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
27071455What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.